Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Comprehensive Analysis: Upa Outshines Dupi Across Key Measures
Dermatology experts analyze the superior outcomes of upadacitinib compared with dupilumab across key efficacy measures in atopic dermatitis treatment.
EP: 1.Evaluating Treatment Efficacy: Identifying and Managing AD Flares in Systemic Therapy Patients
EP: 2.Composite Scores and Quality of Life: A New Standard for AD Management
EP: 3.From Trial to Practice: Applying Study Results to Real-World AD Management
Now Viewing
EP: 4.Comprehensive Analysis: Upa Outshines Dupi Across Key Measures
EP: 5.From Clinic to Practice: Translating AD Trial Data
EP: 6.Final Thoughts: The Importance of Comparative Studies in AD
EP: 7.Improved Quality of Life: Upadacitinib's Role in Managing AD
Recent Videos
Related Content
